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 Introduction 
 Intravenous immunoglobulin (IVIg) is a common therapy for 
patients with immune thrombocytopenia (ITP). The initial response 
rate for IVIg is 80% 1 and is typically rapid, with some patients 
responding in 24 hours, although usually in 2–4 days. 2 When IVIg 
is used alone, the response is relatively short, averaging around 
2–4 weeks. Potential side effects include headache, renal failure, 
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the recommended dose of 1 g/kg/day, and 324 of these 671 
(48.2%) were either given on a single day, or had a second dose 
after an adequate interval to allow for a response assessment. 
Three hundred and forty-seven (51.7%) treatments involved the 
use of additional doses given in a manner not endorsed by the 
guidelines; 324 had IVIg over two consecutive days, three were 
dosed over 5 days and 20 received a different dosing regimen. 
The platelet response following treatment with 1 g/kg on a 
single day was non-inferior to when IVIg was given over two 
consecutive days. 
 Not only do these data suggest that we may be spending 
more money than we should and exposing our patients 
to unnecessary risk by using signiﬁcantly more IVIg than 
is recommended to treat ITP, but they also show that it is 
possible to collect valuable health data rapidly utilising minimal 
resources, by coordinating audit activity across the country with 
research networks such as HaemSTAR. We intend to repeat this 
national audit model annually with other important questions in 
haematology. ■ 
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thrombosis and transfusion-transmitted infection. The cost of IVIg 
is signiﬁcant, averaging £400 for 10 g. 3 Historic dosing regimens for 
IVIg are either 1 g/kg/day for 1–2 days or 0.4 g/kg/day for 5 days. 4 
There are data to suggest an increased likelihood of response with 
1 g/kg/day for 1–2 days than with 0.4 g/kg/day for 5 days. 5 Recent 
guidance from NHS England recommends 1 g/kg for 1 day, with a 
second dose of 1 g/kg at 7 days only if there is failure to achieve 
a haemostatically adequate platelet count. 6 Using the optimal 
dosing regimen is important for maximum efﬁcacy, the avoidance 
of side effects and prudent healthcare. 
 HaemSTAR (Haematology Specialty Trainee Audit and Research) 
is a UK-wide network of clinical haematology registrars that is 
supported by the National Institute of Health Research (NIHR) 
Haematology Clinical Research Network (CRN). We have members 
in each NIHR local CRN who coordinate local research activity and 
involvement of other participants as is needed. Our overarching 
aim is to promote clinical research in non-malignant haematology. 
One way that we intend to do this is by enabling effective transition 
of worthy local audits to a national scale. 
 Methods 
 This project aimed to audit the IVIg prescribing practices for 
treatment of ITP in the UK. Data from a 5-year period between 
2013 and 2018 were eligible for inclusion. The primary outcome 
measure was the proportion of IVIg treatments that were 
dosed according to the 2011 American Society of Hematology 
guidelines. 4 We also collected data on concomitant treatments and 
platelet count responses. We aimed to use this project to develop a 
generalisable methodology for future mass participation audits in 
non-malignant haematology. 
 With competitively won support of a data manager from the West 
Midlands Local CRN, we set up a data collection tool on a secure 
server running the Research Electronic Data Capture (REDCap) 
web application. 7 With the help of our network, in late 2018, 134 
collaborators across 39 hospital sites inputted data from the IVIg 
treatment episodes of 978 adult patients with ITP, over the course 
of just 80 days. This was all at no extra ﬁnancial cost to the NHS. 
 Results and discussion 
 Nine hundred and ﬁfty-six treatment episodes of IVIg were 
recorded with enough data for inclusion in the assessment of 
the primary outcome measure. Of these, 671 (70.2%) used 
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